Trial Profile
The effect of ivacaftor (VX-770, registered in Australia as Kalydeco) on exocrine pancreatic function in patients 6 years and older with cystic fibrosis and at least one copy of the G551D CFTR mutation and who are naive for ivacaftor
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 24 Jun 2016
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 29 Jul 2014 New trial record